A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis

NCT00295282 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: MDX-1100 (anti-CXCL10 human monoclonal antibody)

Sponsor

Bristol-Myers Squibb